Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholecystitis01:20

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Equity in medical school interviews: a cross-sectional analysis of school type, gender, and widening participation status.

BMC medical education·2026
Same author

Transcriptional profiling of the Crocodylus porosus liver cell response to Kunjin virus reveal novel insights into the host-virus interface.

Microbial pathogenesis·2026
Same author

A novel hookworm vaccine candidate identified through immunomic profiling of human protective immunity.

International journal for parasitology·2026
Same author

Transgenic hookworm secretes anti-tetrodotoxin human single chain antibody.

Nature communications·2026
Same author

Advances in vaccine development through the controlled human infection models for hookworm and schistosomiasis.

PLoS neglected tropical diseases·2026
Same author

Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers.

Science translational medicine·2026

Related Experiment Video

Updated: Jun 24, 2026

Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma
09:19

Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma

Published on: July 14, 2022

3.7K

Cholangiocarcinoma.

Paul J Brindley1, Melinda Bachini2, Sumera I Ilyas3

  • 1Department of Microbiology, Immunology & Tropical Medicine, and Research Center for Neglected Diseases of Poverty, School of Medicine and Health Sciences, George Washington University, Washington, DC, USA.

Nature Reviews. Disease Primers
|September 10, 2021
PubMed
Summary
This summary is machine-generated.

Cholangiocarcinoma (CCA) is a deadly bile duct cancer. Research highlights its subtypes, causes like liver flukes and inflammation, and emerging targeted therapies focusing on genetic drivers and the immune microenvironment.

More Related Videos

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

451
Laparoscopic Left Hemihepatectomy Combined with Caudate Lobe Resection
07:22

Laparoscopic Left Hemihepatectomy Combined with Caudate Lobe Resection

Published on: April 11, 2025

410

Related Experiment Videos

Last Updated: Jun 24, 2026

Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma
09:19

Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma

Published on: July 14, 2022

3.7K
Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

451
Laparoscopic Left Hemihepatectomy Combined with Caudate Lobe Resection
07:22

Laparoscopic Left Hemihepatectomy Combined with Caudate Lobe Resection

Published on: April 11, 2025

410

Area of Science:

  • Hepatobiliary oncology
  • Cancer genetics
  • Immunotherapy

Background:

  • Cholangiocarcinoma (CCA) is a lethal adenocarcinoma with intrahepatic, perihilar, and distal subtypes.
  • Causes include liver fluke infection, chronic biliary inflammation (choledocholithiasis, primary sclerosing cholangitis), and often unknown factors.
  • While praziquantel helps against liver fluke-induced CCA, reinfection is common, necessitating new strategies like vaccination.

Purpose of the Study:

  • To review the distinct characteristics of CCA subtypes.
  • To discuss current and potential therapeutic strategies.
  • To highlight recent genetic insights and future research directions.

Main Methods:

  • Review of existing literature on CCA pathogenesis, genetics, and treatment.
  • Analysis of genetic aberrations driving intrahepatic CCA.
  • Exploration of immunotherapeutic approaches targeting the tumor microenvironment.

Main Results:

  • CCA subtypes exhibit unique genetic profiles, clinical presentations, and treatment responses.
  • Specific genetic aberrations (FGFR2 fusions, IDH1 mutations) are key drivers in non-fluke intrahepatic CCA and are therapeutically targetable.
  • Targeting the desmoplastic tumor microenvironment presents a promising avenue for treatment.

Conclusions:

  • CCA remains a highly lethal malignancy requiring further research.
  • Advances in understanding CCA genetics and the tumor immune microenvironment offer new therapeutic possibilities.
  • Improved patient outcomes necessitate continued scientific and clinical investigation.